Advertisement

Drug Safety

, Volume 41, Issue 8, pp 745–752 | Cite as

Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems

  • Emanuel Raschi
  • Anna Girardi
  • Elisabetta Poluzzi
  • Emanuele Forcesi
  • Francesca Menniti-Ippolito
  • Gabriela Mazzanti
  • Fabrizio De Ponti
short communication

Abstract

Introduction

Food supplements containing red yeast rice (RYR) are proposed as an alternative in statin-intolerant patients, although they actually contain natural statin(s) and their safety in clinical practice is still incompletely characterized. We described and compared adverse events (AEs) associated with RYR products submitted to reporting systems maintained by the Food and Drug Administration (FDA), with a focus on liver and muscular events.

Methods

We extracted RYR-related AEs from the FDA Adverse Event Reporting System (FAERS) [first quarter (Q1)-2004 to Q2-2016], a drug-based archive, and the Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS) (Q1-2004 to Q1-2017). Disproportionality via reporting odds ratio (ROR) with 95% confidence interval (CI) calculation and case-by-case inspection were performed, with a focus on muscular and hepatic AEs.

Results

One thousand three hundred AEs were extracted from FAERS (RYR mainly reported as a concomitant agent), whereas only 159 AEs were found in CAERS (RYR recorded mainly as a suspect agent). In FAERS, a large number of reports emerged for “general disorders and administration site conditions,” whereas CAERS received also a high number of reports for “investigations” and “musculoskeletal and connective tissue disorders”. Disproportionality analyses confirmed higher reporting of serious muscular and liver injuries: in FAERS, five cases of hepatic disorders (ROR = 13.71; 95% CI 5.44–34.57); in CAERS, 27 cases of rhabdomyolysis/myopathy (8.44; 5.44–13.10).

Conclusions

Notwithstanding recognized limitations, these findings strengthen the importance of exploring multiple databases in safety assessment of RYR products, which should be monitored by clinicians for muscular and hepatic safety, and call for urgent review by policymakers to harmonize their regulatory status.

Notes

Acknowledgements

E.R. conceived and designed the study, provided guidance with regard to data analysis, and drafted the first version of the manuscript; A.G. and E.F. analyzed the data and provided substantial contributions to data interpretation and discussion; E.P., F.M.I., G.M. and F.D.P. provided substantial contributions to the study design, data interpretation and discussion; all authors critically revised the content and approved the final version of the manuscript.

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this study. Authors at the University of Bologna (E.R., A.G., E.P., E.F., F.D.P.) are supported by Institutional Research Funds (Ricerca Fondamentale Orientata).

Conflicts of Interest

Emanuel Raschi, Anna Girardi, Elisabetta Poluzzi, Emanuele Forcesi, Francesca Menniti-Ippolito, Gabriela Mazzanti and Fabrizio De Ponti declare no potential conflicts of interest relevant to the content of the manuscript.

Supplementary material

40264_2018_661_MOESM1_ESM.pdf (292 kb)
Supplementary Material 1 Disproportionality analysis according to relevant System Organ Classes (SOCs). na: not applicable (number of cases <3). The total count exceeds the number of AEs because a given sign/symptoms (PT of the MedDRA terminology) may be classified in different SOCs (PDF 292 kb)
40264_2018_661_MOESM2_ESM.pdf (241 kb)
Supplementary Material 2 Case-by-case analysis of serious reports (SMQs for muscular or liver toxicities) where RYR was recorded as suspect in FAERS (PDF 242 kb)

References

  1. 1.
    Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999–2012. JAMA. 2016;316:1464–74.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. 2002. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32002L0046&from=EN. Accessed 15 Feb 2018.
  3. 3.
    Santini A, Cammarata SM, Capone G, Ianaro A, Tenore G, Pani L, Novellino E. Nutraceuticals: opening the debate for a regulatory framework. Br J Clin Pharmacol. 2018.  https://doi.org/10.1111/bcp.13496.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Menniti-Ippolito F, Mazzanti G, Santuccio C, Moro PA, Calapai G, Firenzuoli F, et al. Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf. 2008;17:626–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Vitalone A, Menniti-Ippolito F, Moro PA, Firenzuoli F, Raschetti R, Mazzanti G. Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian National Institute of Health. Eur J Clin Pharmacol. 2011;67:215–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Vitalone A, Menniti-Ippolito F, Raschetti R, Renda F, Tartaglia L, Mazzanti G. Surveillance of suspected adverse reactions to herbal products used as laxatives. Eur J Clin Pharmacol. 2012;68:231–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Pokladnikova J, Meyboom RH, Meincke R, Niedrig D, Russmann S. Allergy-like immediate reactions with herbal medicines: a retrospective study using data from VigiBase(R). Drug Saf. 2016;39:455–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Timbo BB, Chirtel SJ, Ihrie J, Oladipo T, Velez-Suarez L, Brewer V, et al. A review of dietary supplement adverse event report data from the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004–2013. Ann Pharmacother. 2017.  https://doi.org/10.1177/1060028017744316.PubMedGoogle Scholar
  9. 9.
    Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Agostoni C, Bresson JL, Fairweather-Tait S, Flynn A, Golly I, Korhonen H, et al. Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2304–20.Google Scholar
  11. 11.
    Childress L, Gay A, Zargar A, Ito MK. Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol. 2013;7:117–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170:1722–7.PubMedGoogle Scholar
  13. 13.
    Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7:133–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. Eur J Prev Cardiol. 2017;24:1431–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on “Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017;27:2–17.CrossRefPubMedGoogle Scholar
  16. 16.
    Catapano AL, Graham I, De BG, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.CrossRefPubMedGoogle Scholar
  17. 17.
    Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain—a systematic review and meta-analysis. Atherosclerosis. 2015;240:415–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145(6):474–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med. 2008;149:516–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66:572–4.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Philibert C, Bres V, Jean-Pastor MJ, Guy C, Lebrun-Vignes B, Robin P, et al. Red yeast-rice-induced muscular injuries: analysis of French pharmacovigilance database and literature review. Therapie. 2016.  https://doi.org/10.2515/therapie/2015053.PubMedGoogle Scholar
  22. 22.
    Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83:894–908.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Opinion of the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) on the risks associated with the presence of ‘red yeast rice’ in food supplements. https://www.anses.fr/fr/system/files/NUT2012sa0228EN.pdf. Accessed 15 Feb 2018.
  24. 24.
    CFSAN adverse event Reporting System (CAERS)—Data Files. https://www.fda.gov/Food/ComplianceEnforcement/ucm494015.htm. Accessed 15 Feb 2018.
  25. 25.
    FDA Adverse Event Reporting System (FAERS): Latest quarterly data files. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed 15 Feb 2018.
  26. 26.
    Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 265–302.Google Scholar
  27. 27.
    Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Macia-Martinez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39:29–43.CrossRefPubMedGoogle Scholar
  29. 29.
    Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol. 1998;45:496–500.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rodrigues E, Barnes J. Pharmacovigilance of herbal medicines: the potential contributions of ethnobotanical and ethnopharmacological studies. Drug Saf. 2013;36:1–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Dujovne CA. Red yeast rice preparations: are they suitable substitutions for statins? Am J Med. 2017;130:1148–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Russo R, Gallelli L, Cannataro R, Perri M, Calignano A, Citraro R, et al. When nutraceuticals reinforce drugs side effects: a case report. Curr Drug Saf. 2016;11:264–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Fung WT, Subramaniam G, Lee J, Loh HM, Leung PH. Assessment of extracts from red yeast rice for herb-drug interaction by in vitro and in vivo assays. Sci Rep. 2012;2:298.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Liu Z, Chen P. A case of erectile dysfunction induced by red yeast rice in lipid-lowering therapy. Phytother Res. 2018.  https://doi.org/10.1002/ptr.6025.Google Scholar
  35. 35.
    De Backer GG. Food supplements with red yeast rice: more regulations are needed. Eur J Prev Cardiol. 2017;24:1429–30.CrossRefPubMedGoogle Scholar
  36. 36.
    Lachenmeier DW, Steffen C, el-Atma O, Maixner S, Lobell-Behrends S, Kohl-Himmelseher M. What is a food and what is a medicinal product in the European Union? Use of the benchmark dose (BMD) methodology to define a threshold for “pharmacological action”. Regul Toxicol Pharmacol. 2012;64:286–95.CrossRefPubMedGoogle Scholar
  37. 37.
    BVL/BfArM, Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) und das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). 2016. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/abgrenzung/Expertenkommission/stellungnahmen/2016-02.pdf?__blob=publicationFile&v=5. Accessed 15 Feb 2018.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmacology Unit, Department of Medical and Surgical SciencesAlma Mater Studiorum - University of BolognaBolognaItaly
  2. 2.National Centre for Drug Research and EvaluationNational Institute of HealthRomeItaly
  3. 3.Department of Physiology and Pharmacology “Vittorio Erspamer”Sapienza University of RomeRomeItaly

Personalised recommendations